where is the best injection site for semaglutide Ozempic Sites: Stomach, Arms, or Thighs? What to Know about GLP-1

Cold-chain storage requirements for certain injectable therapies create additional logistical complexities

This makes it a less intimidating option for many patients, especially those with a fear of needles or who struggle with injectable therapies

Expert guidance from our medical professionals who understand your unique journey and create customized treatment plans for optimal results

that path is cash-pay everywhere

First cardiovascular safety trial to demonstrate that a GLP-1R agonist reduces MACE and microvascular (including renal) events in patients with T2DM and high cardiovascular risk

It demonstrated to have a safety profile similar to GLP-1RA not increasing the risk of hypoglycemia ( In the SURPASS-2 study, TZP at the dose of 5, 10, and 15 mg were compared to the GLP-1RA semaglutide (1 mg once weekly) in patients not well controlled in therapy only with metformin ( 1c ( The SURPASS-3 study was started to study the efficacy and safety of TZP versus basal insulin degludec in diabetic patients inadequately controlled by metformin with or without an SGLT2-i for 52 weeks ( In the 52-week SURPASS-4 trial TZP was tested versus insulin glargine in diabetic adults and a high CV risk below not sufficient GC at baseline and in therapy with one to three oral glucose-lowering drugs (metformin, sulfonylurea, SGLT2-i)